A recently announced initiative between Pfizer and the Trump administration to lower U.S. drug prices will likely have minimal effects at the pharmacy counter, The New York Times reported Oct. 1.  On Sept. 30, Pfizer CEO Albert Bourla, PhD, said the company plans to sell nearly all of its drugs to Medicaid at similar prices found in other high-income countries, reduce medication costs for consumers between 50% and 100%, and invest $90 billion in domestic manufacturing — sidestepping President Donald Trump’s proposed tariffs on brand-name drugs. 

The same day, the White House unveiled plans for a “TrumpRx” website, which would allow U.S. residents to purchase discounted Pfizer medications through a direct-to-consumer model. The website is expected to launch in early 2026, according to the

See Full Page